192 related articles for article (PubMed ID: 28472637)
1. Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer.
Karaki S; Benizri S; Mejías R; Baylot V; Branger N; Nguyen T; Vialet B; Oumzil K; Barthélémy P; Rocchi P
J Control Release; 2017 Jul; 258():1-9. PubMed ID: 28472637
[TBL] [Abstract][Full Text] [Related]
2. The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer.
Choi SY; Xue H; Wu R; Fazli L; Lin D; Collins CC; Gleave ME; Gout PW; Wang Y
Clin Cancer Res; 2016 Jun; 22(11):2721-33. PubMed ID: 26755530
[TBL] [Abstract][Full Text] [Related]
3. Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer.
Baylot V; Katsogiannou M; Andrieu C; Taieb D; Acunzo J; Giusiano S; Fazli L; Gleave M; Garrido C; Rocchi P
Mol Ther; 2012 Dec; 20(12):2244-56. PubMed ID: 22893039
[TBL] [Abstract][Full Text] [Related]
4. TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression.
Baylot V; Karaki S; Rocchi P
Results Probl Cell Differ; 2017; 64():255-261. PubMed ID: 29149413
[TBL] [Abstract][Full Text] [Related]
5. Lipid-modified oligonucleotide conjugates: Insights into gene silencing, interaction with model membranes and cellular uptake mechanisms.
Ugarte-Uribe B; Grijalvo S; Pertíñez SN; Busto JV; Martín C; Alagia A; Goñi FM; Eritja R; Alkorta I
Bioorg Med Chem; 2017 Jan; 25(1):175-186. PubMed ID: 27810441
[TBL] [Abstract][Full Text] [Related]
6. TCTP is an androgen-regulated gene implicated in prostate cancer.
Kaarbø M; Storm ML; Qu S; Wæhre H; Risberg B; Danielsen HE; Saatcioglu F
PLoS One; 2013; 8(7):e69398. PubMed ID: 23894469
[TBL] [Abstract][Full Text] [Related]
7. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
8. DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
Le TK; Cherif C; Omabe K; Paris C; Lannes F; Audebert S; Baudelet E; Hamimed M; Barbolosi D; Finetti P; Bastide C; Fazli L; Gleave M; Bertucci F; Taïeb D; Rocchi P
Mol Ther; 2023 Feb; 31(2):471-486. PubMed ID: 35965411
[TBL] [Abstract][Full Text] [Related]
9. Polyethyleneimine grafted with pluronic P85 enhances Ku86 antisense delivery and the ionizing radiation treatment efficacy in vivo.
Belenkov AI; Alakhov VY; Kabanov AV; Vinogradov SV; Panasci LC; Monia BP; Chow TY
Gene Ther; 2004 Nov; 11(22):1665-72. PubMed ID: 15470482
[TBL] [Abstract][Full Text] [Related]
10. [Antisense oligodeoxynucleotide therapy for castration-resistant prostate cancer].
Miyake H; Fujisawa M
Nihon Rinsho; 2014 Dec; 72(12):2121-5. PubMed ID: 25518344
[TBL] [Abstract][Full Text] [Related]
11. Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody.
Meissner JM; Toporkiewicz M; Czogalla A; Matusewicz L; Kuliczkowski K; Sikorski AF
J Control Release; 2015 Dec; 220(Pt A):515-528. PubMed ID: 26585505
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of translationally controlled tumor protein inhibits growth, migration and invasion of lung cancer cells.
Wang L; Tang Y; Zhao M; Mao S; Wu L; Liu S; Liu D; Zhao G; Wang X
Life Sci; 2018 Jan; 193():292-299. PubMed ID: 28970113
[TBL] [Abstract][Full Text] [Related]
13. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound targeted microbubble destruction for novel dual targeting of HSP72 and HSC70 in prostate cancer.
Wang HH; Song YX; Bai M; Jin LF; Gu JY; Su YJ; Liu L; Jia C; Du LF
Asian Pac J Cancer Prev; 2014; 15(3):1285-90. PubMed ID: 24606454
[TBL] [Abstract][Full Text] [Related]
16. TP53INP1 as new therapeutic target in castration-resistant prostate cancer.
Giusiano S; Baylot V; Andrieu C; Fazli L; Gleave M; Iovanna JL; Taranger-Charpin C; Garcia S; Rocchi P
Prostate; 2012 Sep; 72(12):1286-94. PubMed ID: 22213058
[TBL] [Abstract][Full Text] [Related]
17. Gene silencing of translationally controlled tumor protein (TCTP) by siRNA inhibits cell growth and induces apoptosis of human prostate cancer cells.
Gnanasekar M; Thirugnanam S; Zheng G; Chen A; Ramaswamy K
Int J Oncol; 2009 May; 34(5):1241-6. PubMed ID: 19360337
[TBL] [Abstract][Full Text] [Related]
18. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
19. ACSL4 promotes prostate cancer growth, invasion and hormonal resistance.
Wu X; Deng F; Li Y; Daniels G; Du X; Ren Q; Wang J; Wang LH; Yang Y; Zhang V; Zhang D; Ye F; Melamed J; Monaco ME; Lee P
Oncotarget; 2015 Dec; 6(42):44849-63. PubMed ID: 26636648
[TBL] [Abstract][Full Text] [Related]
20. Delivery of antisense oligonucleotide using polyethylenimine-based lipid nanoparticle modified with cell penetrating peptide.
Yang S; Wang D; Sun Y; Zheng B
Drug Deliv; 2019 Dec; 26(1):965-974. PubMed ID: 31544540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
